In April 2021, we transitioned to a holding company structure and started as ASKA Pharmaceutical Holdings Co., Ltd.
In the pharmaceutical business, which is our core activity, the business environment is becoming increasingly challenging as measures to curb medical expenses are vigorously promoted, including annual NHI drug price revisions. In order to respond appropriately to these changes in the environment, we have moved to a holding company structure with is based on three business pillars. The core pillar being our "Pharmaceutical products", and centred around this core is our "Veterinary pharmaceutical products" and "Testing and Diagnostic products" divisions. The purpose of transitioning to a holding company structure is to enhance our flexibly for decision making and strengthening our corporate governance.
At the same time, in fiscal year 2021 we will launch a new medium-term management plan ending in fiscal year 2025. Under the new plan, in order to continue to be a company that is trusted by society, we will transform into a leading specialty company in our core pharmaceutical business. At the same time, we will continue to contribute by developing businesses that reflect society needs by promoting open innovation. Furthermore, we will aim to be a total healthcare company with related businesses in the entire healthcare market of "prevention, testing and diagnostics, treatment, and post-treatment," centered on our business up to the present time.
In 1920, Yamaguchi Yasohachi, our founder, established Teikoku Hormone Research Institute, and began research, manufacturing, and sales of hormone formulations based on the unique idea of creating useful drugs from animal organs. Based on the drug discovery capabilities we have cultivated over our 100-year history, we will continue to take on new challenges under corporate philosophy of "Contribute toward the improvement of people’s health and progress in society through the development of innovative products"
We would appreciate your continued understanding and support of our stakeholders.
Takashi Yamaguchi
President, Representative Director
(As of April 1, 2021)